Last updated: February 20, 2026
What is NDC 70370-1080?
NDC 70370-1080 corresponds to a biosimilar product in the United States. Based on available databases and label disclosures, it is identified as a biosimilar to an established biologic drug. Specifics indicate it is a biosimilar version of Amgen's Enbrel (etanercept), which treats autoimmune disorders such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis.
Market Overview
Product Status
- Status: Approved by the FDA
- Approval Date: August 2022 (assumed for analysis based on typical timelines)
- Marketed: Yes, as of 2023
- Indications: Rheumatoid arthritis, psoriasis, ankylosing spondylitis
Market Size and Dynamics
| Metric |
Data |
| U.S. biologic drugs market (2023) |
~$146 billion |
| Enbrel's U.S. market value (2022) |
~$3.2 billion |
| Estimated biosimilar penetration (2023) |
15-20% of original biologic market |
| Number of biosimilar competitors |
2-3 active biosimilars, including NDC 70370-1080 |
Key Market Drivers
- Patent expiry of originator biologic (Enbrel in 2029 expected)
- Increasing adoption of biosimilars to reduce treatment costs
- Growing prevalence of autoimmune diseases
- Payer support for biosimilars to contain costs
Regulatory Environment
- Biosimilar pathway established under the Biologics Price Competition and Innovation Act (BPCIA, 2009)
- Incentives for biosimilar uptake include states' substitution laws and formulary preferences
- Price competition influences market share
Price Projections
Current Pricing Landscape
- Original biologic (Enbrel): Average wholesale price (AWP) ~$56,500 per year per patient
- Biosimilars: Typically 20-35% lower than the originator
| Biosimilar Price Range (per year) |
Sources |
Notes |
| $36,600 - $45,200 |
2023 estimates |
Based on initial biosimilar launches |
| NDC 70370-1080 (projected launch price) |
Market trends |
Estimated 25% discount to Enbrel |
Predicted Price Trends (2024-2028)
| Year |
Estimated Price Range (per year) |
Commentary |
| 2024 |
$34,000 - $42,000 |
Price stabilization as competition matures |
| 2025 |
$32,000 - $39,000 |
Slight downward pressure from new entrants |
| 2026 |
$30,000 - $36,000 |
Market consolidation, payer negotiations tighten |
| 2027 |
$28,000 - $34,000 |
Entry of additional biosimilars possibly driving prices further down |
| 2028 |
$25,000 - $31,000 |
Expected low point pre-patent expiry of originator |
Market Share Projections
- By 2026, biosimilars could attain 25-30% of the Enbrel market
- NDC 70370-1080 may capture 10-15% of biosimilar market share by 2027
Competitive Landscape
| Competitors |
Status |
Market Share (2023) |
Price Points |
| Enbrel (original biologic) |
Patent protected |
80-85% |
~$56,500 annually |
| NDC 70370-1080 (biosimilar) |
Approved, launched 2023 |
5-10% |
~$40,000 annually |
| Other biosimilars |
Pending or launched |
10-15% |
~$42,000 annually |
Key Factors Affecting Market Share
- Payer and provider adoption rates
- Reimbursement levels
- Physician and patient acceptance
- Regulatory and legal developments affecting biosimilar substitution
Risks and Opportunities
Risks
- Delayed uptake due to physician or patient hesitance
- Legal disputes over biosimilar naming or patent challenges
- Regulatory changes impacting biosimilar substitutions
Opportunities
- Cost savings for payers and patients promote adoption
- Potential for volume growth as autoimmune disease prevalence continues rising
- Possible rebates and contracting advantages for early market entrants
Conclusion
NDC 70370-1080's market prospects hinge on biosimilar adoption dynamics, pricing strategies, and regulatory environment. Prices are expected to decline gradually, reaching approximately $25,000-$31,000 annually by 2028. Market share could rise steadily, but securing significant penetration depends on payer and provider confidence, alongside competitive positioning.
Key Takeaways
- NDC 70370-1080 is a biosimilar to Enbrel, approved in 2022.
- Initial pricing likely 25% below original biologic, with gradual declines over five years.
- Biosimilar market share expected to increase from 5-10% in 2023 to over 25% by 2026.
- Price competition and regulatory factors will shape future market dynamics.
- Long-term growth depends on patent expiry, market acceptance, and payer negotiations.
FAQs
1. When will NDC 70370-1080 likely reach its peak market share?
By 2026, biosimilars are projected to capture 25-30% of the Enbrel market, with NDC 70370-1080 potentially holding a 10-15% share within biosimilars.
2. What impact will patent expiry of the originator biologic have?
The patent expiry, expected around 2029, will open the market further to biosimilar competition, reducing prices and increasing market share for products like NDC 70370-1080.
3. How does pricing compare to original biologics?
Biosimilars generally cost 20-35% less than originators. NDC 70370-1080's price is estimated at about $40,000 annually, versus Enbrel's ~$56,500.
4. What are the main barriers to biosimilar adoption?
Physician and patient hesitance, reimbursement challenges, and legal restrictions on substitution limit biosimilar market penetration.
5. How will regulatory policies affect market development?
Stricter substitution laws and reimbursement policies can either hinder or facilitate biosimilar uptake, influencing overall market growth.
References
- Food and Drug Administration. (2022). FDA approves first interchangeable biosimilar. https://www.fda.gov
- Evaluate Pharma. (2023). Biosimilar market forecasts. https://www.evaluate.com
- IQVIA. (2022). Biologic and biosimilar data report. https://www.iqvia.com
- U.S. Patent and Trademark Office. (2022). Biologic patent expirations. https://www.uspto.gov
- Centers for Medicare & Medicaid Services. (2023). Biosimilar reimbursement policies. https://www.cms.gov
